Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NetApp Inc. (NTAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NetApp Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while NetApp Inc. trades at $167.5 (market cap $33.08B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and NetApp Inc. pays a 1.23% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NTAP | |
|---|---|---|
Market Cap | $39.89B | $33.08B |
Sector | Health | Technology |
52-Week High | $491.22 | $181.08 |
52-Week Low | $278.09 | $94.11 |
Enterprise Value | $38.15B | $32.23B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
NetApp (NTAP) trades at $168.87, down 1.67% on the day but up significantly year-to-date, driven by strong AI infrastructure demand. The stock shows bullish technical signals with moving averages aligned positively, while fundamentals reveal robust profitability with an 18.43% net margin and consistent earnings beats. Recent news highlights partnerships and AI workload enhancements, supporting growth momentum.
Outlook remains positive with AI-driven revenue acceleration, though valuation multiples like P/E of 26.59 suggest premium pricing. Risks include competitive pressures and execution challenges in scaling AI offerings. Analyst consensus leans hold with a $167.45 target, indicating limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
